Why the study?
African swine fever causes substantial economic losses, but no effective commercial vaccine is currently available due to the virus's large genome, numerous encoded proteins, and complex particle structure.
Design
Review
Authors
Loading...
ASF vaccine progress remains limited by viral complexity; leaves open the feasibility of a safe, effective commercial product.
This review highlights the challenges and strategies in developing a safe and efficient commercial live-attenuated vaccine against African swine fever.
Chu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: